Your browser doesn't support javascript.
Curbing COVID-19 progression and mortality with traditional Chinese medicine among hospitalized patients with COVID-19: A propensity score-matched analysis.
Tseng, Yu-Hwei; Lin, Sunny Jui-Shan; Hou, Sheng-Mou; Wang, Chih-Hung; Cheng, Shun-Ping; Tseng, Kung-Yen; Lee, Ming-Yung; Lee, Shen-Ming; Huang, Yi-Chia; Lin, Chien-Jung; Lin, Chi-Kuei; Tsai, Tsung-Lung; Lin, Chen-Shien; Cheng, Ming-Huei; Fong, Tieng-Siong; Tsai, Chia-I; Lu, Yu-Wen; Lin, Jung-Chih; Huang, Yi-Wen; Hsu, Wei-Chen; Kuo, Hsien-Hwa; Wang, Li-Hsiang; Liaw, Chia-Ching; Wei, Wen-Chi; Tsai, Keng-Chang; Shen, Yuh-Chiang; Chiou, Wen-Fei; Lin, Jaung-Geng; Su, Yi-Chang.
  • Tseng YH; National Research Institute of Chinese Medicine, Ministry of Health and Welfare, Taipei, Taiwan ROC.
  • Lin SJ; Tri-Service General Hospital, National Defense Medical Center, Taipei, Taiwan ROC.
  • Hou SM; Shin Kong Wu Ho-Su Memorial Hospital, Taipei, Taiwan ROC.
  • Wang CH; Tri-Service General Hospital, National Defense Medical Center, Taipei, Taiwan ROC.
  • Cheng SP; Taipei Hospital, Ministry of Health and Welfare, Taipei, Taiwan ROC.
  • Tseng KY; Chang-Hua Hospital, Ministry of Health and Welfare, Changhua, Taiwan ROC.
  • Lee MY; Department of Data Science and Big Data Analytics, Providence University, Taichung, Taiwan ROC.
  • Lee SM; Department of Statistics, Feng Chia University, Taichung, Taiwan ROC.
  • Huang YC; Tri-Service General Hospital, National Defense Medical Center, Taipei, Taiwan ROC.
  • Lin CJ; Tri-Service General Hospital, National Defense Medical Center, Taipei, Taiwan ROC.
  • Lin CK; Shin Kong Wu Ho-Su Memorial Hospital, Taipei, Taiwan ROC.
  • Tsai TL; Taoyuan General Hospital, Ministry of Health and Welfare, Taoyuan, Taiwan ROC.
  • Lin CS; Taipei Hospital, Ministry of Health and Welfare, Taipei, Taiwan ROC.
  • Cheng MH; Feng Yuan Hospital, Ministry of Health and Welfare, Taichung, Taiwan ROC.
  • Fong TS; Chang-Hua Hospital, Ministry of Health and Welfare, Changhua, Taiwan ROC.
  • Tsai CI; Taichung Veterans General Hospital, Taichung, Taiwan ROC.
  • Lu YW; Chang Bing Show Chwan Memorial Hospital, Changhua, Taiwan ROC.
  • Lin JC; Chung Shan Medical University Hospital, Taichung, Taiwan ROC.
  • Huang YW; Chang-Hua Hospital, Ministry of Health and Welfare, Changhua, Taiwan ROC.
  • Hsu WC; Taoyuan General Hospital, Ministry of Health and Welfare, Taoyuan, Taiwan ROC.
  • Kuo HH; Taipei Hospital, Ministry of Health and Welfare, Taipei, Taiwan ROC.
  • Wang LH; ChanDer Clinic, Taipei, Taiwan ROC.
  • Liaw CC; National Research Institute of Chinese Medicine, Ministry of Health and Welfare, Taipei, Taiwan ROC.
  • Wei WC; National Research Institute of Chinese Medicine, Ministry of Health and Welfare, Taipei, Taiwan ROC.
  • Tsai KC; National Research Institute of Chinese Medicine, Ministry of Health and Welfare, Taipei, Taiwan ROC.
  • Shen YC; National Research Institute of Chinese Medicine, Ministry of Health and Welfare, Taipei, Taiwan ROC.
  • Chiou WF; National Research Institute of Chinese Medicine, Ministry of Health and Welfare, Taipei, Taiwan ROC.
  • Lin JG; National Research Institute of Chinese Medicine, Ministry of Health and Welfare, Taipei, Taiwan ROC; Chinese Medicine Research Center, China Medical University, Taichung, Taiwan.
  • Su YC; National Research Institute of Chinese Medicine, Ministry of Health and Welfare, Taipei, Taiwan ROC. Electronic address: sychang@nricm.edu.tw.
Pharmacol Res ; 184: 106412, 2022 10.
Article in English | MEDLINE | ID: covidwho-1996480
ABSTRACT

BACKGROUND:

Viral- and host-targeted traditional Chinese medicine (TCM) formulae NRICM101 and NRICM102 were administered to hospitalized patients with COVID-19 during the mid-2021 outbreak in Taiwan. We report the outcomes by measuring the risks of intubation or admission to intensive care unit (ICU) for patients requiring no oxygen support, and death for those requiring oxygen therapy.

METHODS:

This multicenter retrospective study retrieved data of 840 patients admitted to 9 hospitals between May 1 and July 26, 2021. After propensity score matching, 302 patients (151 received NRICM101 and 151 did not) and 246 patients (123 received NRICM102 and 123 did not) were included in the analysis to assess relative risks.

RESULTS:

During the 30-day observation period, no endpoint occurred in the patients receiving NRICM101 plus usual care while 14 (9.27%) in the group receiving only usual care were intubated or admitted to ICU. The numbers of deceased patients were 7 (5.69%) in the group receiving NRICM102 plus usual care and 27 (21.95%) in the usual care group. No patients receiving NRICM101 transitioned to a more severe status; NRICM102 users were 74.07% less likely to die than non-users (relative risk= 25.93%, 95% confidence interval 11.73%-57.29%).

CONCLUSION:

NRICM101 and NRICM102 were significantly associated with a lower risk of intubation/ICU admission or death among patients with mild-to-severe COVID-19. This study provides real-world evidence of adopting broad-spectrum oral therapeutics and shortening the gap between outbreak and effective response. It offers a new vision in our preparation for future pandemics.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: COVID-19 Type of study: Observational study / Prognostic study Topics: Traditional medicine Limits: Humans Language: English Journal: Pharmacol Res Journal subject: Pharmacology Year: 2022 Document Type: Article

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: COVID-19 Type of study: Observational study / Prognostic study Topics: Traditional medicine Limits: Humans Language: English Journal: Pharmacol Res Journal subject: Pharmacology Year: 2022 Document Type: Article